



PATENT
Attorney Docket No. 205884

#16
JB
1/1/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 12 2002

In re Application of:
Ullrich et al.

Art Unit: 1646

TECH CENTER 1600/2900

Application No. 09/600,826

Examiner: Joseph F. Murphy

Filed: September 7, 2000

For: USE OF INHIBITORS FOR THE
TREATMENT OF RTK-
HYPERFUNCTION-INDUCED
DISORDERS, PARTICULARLY
CANCER

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the requirement for restriction dated August 30, 2002, please consider the following remarks.

REMARKS

The Requirement for Restriction

The Office has set forth the following requirement for restriction:

- (i) claims 33-46, drawn to a method for treatment of an RTK-hyperfunction induced disorder with an inhibitor of FGFR-4,
- (ii) claims 47-54, drawn to a mutated FGFR-4 polypeptide,
- (iii) claims 55-59, drawn to a method of diagnosing an RTK-hyperfunction induced disorder by determining the presence of a mutated FGFR-4 nucleic acid,
- (iv) claims 55-59, drawn to a method of diagnosing an RTK-hyperfunction induced disorder by determining the presence of a mutated FGFR-4 protein,
- (v) claim 60, drawn to a method of identifying an inhibitor of tyrosine kinase activity by contacting a potential inhibitor with FGFR-4,

12/11/2002 WABDELRI 00000119 121216 09600826
01 FC:1252 400.00 CH